AR073513A1 - ORTO - AMINOANILIDS FOR CANCER TREATMENT - Google Patents
ORTO - AMINOANILIDS FOR CANCER TREATMENTInfo
- Publication number
- AR073513A1 AR073513A1 ARP090103531A ARP090103531A AR073513A1 AR 073513 A1 AR073513 A1 AR 073513A1 AR P090103531 A ARP090103531 A AR P090103531A AR P090103531 A ARP090103531 A AR P090103531A AR 073513 A1 AR073513 A1 AR 073513A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- halogen
- lower alkyl
- nr4r5
- unsubstituted
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Procesos para la obtencion de dichos compuestos y medicamentos que contengan dichos compuestos. Los compuestos poseen actividad antiproliferante y actividad inductora de la diferenciacion y por ello son utiles para el tratamiento de enfermedades, por ejemplo el cáncer de humano o de animales. Reivindicacion 1: Compuestos de formula general (1) en la que R1 es hidrogeno; halogeno; alquilo inferior, sin sustituir o sustituido una o varias veces por halogeno; cicloalquilo; ciano; alcoxi inferior; R2 es un resto de formula (2), en el que R3 es un anillo heterociclilo de 3-10 eslabones, sin sustituir o sustituido una o varias veces por halogeno, alquilo inferior, hidroxi, -C(O)-alquilo inferior, =O o NR4R5; o es NR4R5; R4/R5 con independencia entre sí son hidrogeno o alquilo inferior; n es el numero 0, 1, 2 o 3, y cuando n = 0, R3 deberá ser un anillo heterociclilo de 3-10 eslabones conectado a través de un átomo de carbono; X es C o N; y las sales, mezclas racémicas, enantiomeros, isomeros opticos o formas tautomeras farmacéuticamente activas de los mismos.Processes for obtaining said compounds and medications containing said compounds. The compounds possess antiproliferative activity and inducing activity of differentiation and are therefore useful for the treatment of diseases, for example human or animal cancer. Claim 1: Compounds of general formula (1) wherein R1 is hydrogen; halogen; lower alkyl, unsubstituted or substituted once or several times by halogen; cycloalkyl; cyano; lower alkoxy; R2 is a residue of formula (2), wherein R3 is a 3-10 link heterocyclyl ring, unsubstituted or substituted once or several times by halogen, lower alkyl, hydroxy, -C (O) -alkyl lower, = O or NR4R5; or is NR4R5; R4 / R5 independently of each other are hydrogen or lower alkyl; n is the number 0, 1, 2 or 3, and when n = 0, R3 must be a 3-10 link heterocyclyl ring connected through a carbon atom; X is C or N; and salts, racemic mixtures, enantiomers, optical isomers or pharmaceutically active tautomeric forms thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164509 | 2008-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073513A1 true AR073513A1 (en) | 2010-11-10 |
Family
ID=41716278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103531A AR073513A1 (en) | 2008-09-17 | 2009-09-15 | ORTO - AMINOANILIDS FOR CANCER TREATMENT |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8202866B2 (en) |
| EP (1) | EP2334658A2 (en) |
| JP (1) | JP2011526936A (en) |
| KR (1) | KR20110043767A (en) |
| CN (1) | CN102149678A (en) |
| AR (1) | AR073513A1 (en) |
| AU (1) | AU2009294668A1 (en) |
| BR (1) | BRPI0918508A2 (en) |
| CA (1) | CA2734349A1 (en) |
| IL (1) | IL210066A0 (en) |
| MX (1) | MX2011002574A (en) |
| TW (1) | TWI378093B (en) |
| WO (1) | WO2010031708A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| CA2828524C (en) | 2011-02-28 | 2020-01-07 | Repligen Corporation | Histone deacetylase inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8781041B2 (en) * | 2012-07-31 | 2014-07-15 | Hewlett-Packard Development Company, L.P. | Reducing noise in a sequence of data by linear and non-linear estimation |
| JP6503338B2 (en) | 2013-03-15 | 2019-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | HDAC inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1643264A1 (en) * | 1967-12-20 | 1971-06-09 | Basf Ag | Process for the preparation of aminoanilides |
| IT1033046B (en) | 1970-10-31 | 1979-07-10 | Finotto Martino | PROCESS FOR MANUFACTURING SUBSTITUTED BENZIMIDAZOLES |
| EP1429765A2 (en) * | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2007087130A2 (en) | 2006-01-12 | 2007-08-02 | Merck & Co., Inc. | Hydroxyalkylarylamide derivatives |
| JP2009528354A (en) * | 2006-02-28 | 2009-08-06 | メルク エンド カムパニー インコーポレーテッド | Inhibitors of histone deacetylase |
| JP2010513326A (en) * | 2006-12-19 | 2010-04-30 | メシルジーン インコーポレイテッド | Inhibitors of histone deacetylase and prodrugs thereof |
| WO2008087514A2 (en) * | 2007-01-17 | 2008-07-24 | Orchid Research Laboratories Limited | Hdac inhibitors |
| WO2009095324A1 (en) | 2008-01-29 | 2009-08-06 | F. Hoffmann-La Roche Ag | Novel n-(2-amino-phenyl)-amide derivatives |
| WO2009138338A1 (en) * | 2008-05-16 | 2009-11-19 | F. Hoffmann-La Roche Ag | Novel n-(2-amino-phenyl)-acrylamides |
| JP2011150917A (en) * | 2010-01-22 | 2011-08-04 | Nippon Soken Inc | Gas diffusion layer, and fuel cell having the same |
-
2009
- 2009-08-19 US US12/543,527 patent/US8202866B2/en not_active Expired - Fee Related
- 2009-09-07 JP JP2011517178A patent/JP2011526936A/en active Pending
- 2009-09-07 BR BRPI0918508A patent/BRPI0918508A2/en not_active IP Right Cessation
- 2009-09-07 EP EP09782677A patent/EP2334658A2/en not_active Withdrawn
- 2009-09-07 CA CA2734349A patent/CA2734349A1/en not_active Abandoned
- 2009-09-07 KR KR1020117006073A patent/KR20110043767A/en not_active Application Discontinuation
- 2009-09-07 CN CN2009801356932A patent/CN102149678A/en active Pending
- 2009-09-07 AU AU2009294668A patent/AU2009294668A1/en not_active Abandoned
- 2009-09-07 WO PCT/EP2009/061533 patent/WO2010031708A2/en active Application Filing
- 2009-09-07 MX MX2011002574A patent/MX2011002574A/en not_active Application Discontinuation
- 2009-09-15 AR ARP090103531A patent/AR073513A1/en not_active Application Discontinuation
- 2009-09-15 TW TW098131074A patent/TWI378093B/en not_active IP Right Cessation
-
2010
- 2010-12-16 IL IL210066A patent/IL210066A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110043767A (en) | 2011-04-27 |
| IL210066A0 (en) | 2011-02-28 |
| US20100069328A1 (en) | 2010-03-18 |
| MX2011002574A (en) | 2011-04-26 |
| AU2009294668A1 (en) | 2010-03-25 |
| US8202866B2 (en) | 2012-06-19 |
| WO2010031708A3 (en) | 2010-08-05 |
| TWI378093B (en) | 2012-12-01 |
| EP2334658A2 (en) | 2011-06-22 |
| WO2010031708A2 (en) | 2010-03-25 |
| BRPI0918508A2 (en) | 2015-12-08 |
| CN102149678A (en) | 2011-08-10 |
| TW201014834A (en) | 2010-04-16 |
| CA2734349A1 (en) | 2010-03-25 |
| JP2011526936A (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073513A1 (en) | ORTO - AMINOANILIDS FOR CANCER TREATMENT | |
| NI200700270A (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME | |
| UY30267A1 (en) | NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| AR065128A1 (en) | DERIVATIVES OF 2-AMINOOXAZOLINAS AS LIGANDOS TAAR1. OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES | |
| UY29633A1 (en) | OXINDOL DERIVATIVES | |
| ECSP066302A (en) | OMEGA-CARBOXIARIL-DIFENIL-UREA REPLACED WITH FLUORINE FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS | |
| AR079327A1 (en) | DERIVATIVES OF 2-AMINO-5,5-DIFLUOR -5,6-DIHIDRO-4H- (1,3) OXAZIN-4-IL) PHENYL) -AMIDA | |
| GT200600429A (en) | ORGANIC COMPOUNDS | |
| UY27665A1 (en) | NEW DERIVATIVES OF PIRIDINA AND PIRIMIDINA | |
| UY27666A1 (en) | NEW DERIVATIVES OF PIRIDINA AND QUINOLINA | |
| ECSP045003A (en) | New dihydro-pteridinones, procedures for their preparation and their use as medicines. | |
| UY31126A1 (en) | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYPOSINE KINASE ACTIVITY OF THE JANUS CINASES | |
| AR054735A1 (en) | PROCESS FOR OBTAINING A PIPERAZINE DERIVATIVE | |
| ECSP066549A (en) | BICYCLIC PIRAZOLILO AND IMIDAZOLILO COMPOUNDS AND USES OF THE SAME | |
| AR085219A1 (en) | 6-CICLOALQUIL-PIRAZOLOPIRIMIDINONAS FOR THE TREATMENT OF CNS DISORDERS | |
| UY30835A1 (en) | 8-ALQUINILXANTINAS AND DERIVATIVES | |
| AR075530A1 (en) | NEW ORTO-AMINOAMIDS FOR CANCER TREATMENT | |
| ECSP11010804A (en) | ORGANIC COMPOUNDS | |
| ECSP088593A (en) | 5- (ARILSULFONIL) -PIRAZOLOPIPERIDINS | |
| PE20070519A1 (en) | DERIVATIVES OF PHENYLMORPHOLINE AND PHENYLTIOMORPHOLINE AS AGONISTS OF ALPHA 2C ADRENORECEPTORS | |
| UY29617A1 (en) | CHEMICAL COMPOUNDS VII | |
| UY32259A (en) | NEW HYDROXYARENE COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND APPLICATIONS | |
| UY29184A1 (en) | DERIVATIVES OF SULFONILBENCIMIDAZOL | |
| UY29393A1 (en) | NEW DERIVATIVES OF AMIDAS, ACCEPTABLE PHARMACEUTICAL SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS. | |
| NI200700032A (en) | ARILSULFONYLESTILBEN DERIVATIVES FOR INSOMNIA TREATMENT AND RELATED AFFECTIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |